Melhem Solh

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. doi request reprint Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center
    Melhem Solh
    Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia Electronic address
    Biol Blood Marrow Transplant 22:1403-9. 2016
  2. doi request reprint Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation: better prognosis than systemic relapse
    Melhem Solh
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, 55455, USA
    Biol Blood Marrow Transplant 18:106-12. 2012
  3. doi request reprint Late-onset noninfectious pulmonary complications in adult allogeneic hematopoietic cell transplant recipients
    Melhem Solh
    Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Transplantation 91:798-803. 2011
  4. doi request reprint Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Mul
    Asad Bashey
    Blood and Marrow Transplant Program, Northside Hospital, Atlanta, Georgia Electronic address
    Biol Blood Marrow Transplant 22:125-33. 2016
  5. doi request reprint Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia
    Scott R Solomon
    The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia Electronic address
    Biol Blood Marrow Transplant 22:1816-22. 2016
  6. doi request reprint A prognostic index for survival among mechanically ventilated hematopoietic cell transplant recipients
    Melhem Solh
    Blood and Marrow Transplant Program, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 18:1378-84. 2012
  7. pmc Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide
    Scott R Solomon
    Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA 30342, USA
    Adv Hematol 2016:9736564. 2016
  8. pmc Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants
    Melhem Solh
    Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 17:710-6. 2011

Collaborators

Detail Information

Publications8

  1. doi request reprint Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center
    Melhem Solh
    Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia Electronic address
    Biol Blood Marrow Transplant 22:1403-9. 2016
    ..001) were all associated with a worse GFRS post-HCT. These data suggest that GRFS can be predicted by patient disease risk, stem cell source, and donor type. Importantly, MUDs produce inferior GRFS to MRDs, whereas HIDs do not. ..
  2. doi request reprint Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation: better prognosis than systemic relapse
    Melhem Solh
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, 55455, USA
    Biol Blood Marrow Transplant 18:106-12. 2012
    ..GVHD and its accompanying graft-versus-leukemia effect may better protect BM sites, but patients with EM relapse have better responses to combined therapy and improved survival compared with those with BM relapse...
  3. doi request reprint Late-onset noninfectious pulmonary complications in adult allogeneic hematopoietic cell transplant recipients
    Melhem Solh
    Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Transplantation 91:798-803. 2011
    ..We hereby present a study evaluating the incidence, risk factors, and outcomes of LONIPC in a recent cohort of allogeneic HCT recipients...
  4. doi request reprint Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Mul
    Asad Bashey
    Blood and Marrow Transplant Program, Northside Hospital, Atlanta, Georgia Electronic address
    Biol Blood Marrow Transplant 22:125-33. 2016
    ..59; P = .007). HIDT produced similar long-term survival with lower rates of chronic GVHD than optimally matched MUDT. HIDT should be considered a standard of care option for patients lacking a matched sibling donor...
  5. doi request reprint Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia
    Scott R Solomon
    The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia Electronic address
    Biol Blood Marrow Transplant 22:1816-22. 2016
    ..Given the favorable outcomes associated with alloHCT in acute leukemia and lack of effect of donor type, a strong case can be made for transplanting acute leukemia patients in remission as soon as any donor becomes available. ..
  6. doi request reprint A prognostic index for survival among mechanically ventilated hematopoietic cell transplant recipients
    Melhem Solh
    Blood and Marrow Transplant Program, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 18:1378-84. 2012
    ..Corresponding OS in class B patients was 5% and 15%, respectively. This prognostic index should help guide physicians in counseling HCT patients and their families regarding the use of MV and potential outcomes...
  7. pmc Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide
    Scott R Solomon
    Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA 30342, USA
    Adv Hematol 2016:9736564. 2016
    ..We contrast our results with other published reports of MA haplo-HSCT PT/Cy in the literature and attempt to define the comparative utility of MA haplo-HSCT to other methods of transplantation. ..
  8. pmc Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants
    Melhem Solh
    Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 17:710-6. 2011
    ..Enhanced approaches to accelerate multilineage engraftment could limit the transfusion-associated morbidity and costs accompanying UCB allotransplantation...